Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)

As­traZeneca's Lyn­parza-Imfinzi com­bo clears PhI­II tri­al in ovar­i­an can­cer

As­traZeneca tout­ed pos­i­tive da­ta for its Lyn­parza-Imfinzi block­buster com­bo to­day with a high-lev­el analy­sis from its DUO-O Phase III tri­al, in new­ly di­ag­nosed pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.